Related Experiment Video
Updated: Mar 3, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation
David F Briceño1, Nidhi Madan1, Jorge Romero1
1a Division of Cardiovascular Disease , Montefiore Medical Center, Albert Einstein College of Medicine , Bronx , NY , USA.
Insights
Catheter ablation for atrial fibrillation (AF) requires careful anticoagulation to prevent stroke and bleeding. Uninterrupted anticoagulation strategies and individualized risk assessment are key advances in managing these risks during AF ablation.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Atrial fibrillation (AF) significantly increases morbidity and mortality.
- Catheter ablation for AF (CAAF) is an effective rhythm control treatment for symptomatic patients.
- Periprocedural thromboembolism and bleeding are significant complications of CAAF.
Purpose of the Study:
- To review anticoagulation regimens for minimizing thromboembolic and bleeding risks during CAAF.
- To detail uninterrupted oral anticoagulation and heparin dosing for safe activated clotting time levels.
- To discuss comprehensive risk assessment and anticoagulant pharmacokinetics in CAAF.
Main Methods:
- Review of current literature on anticoagulation strategies in CAAF.
- Analysis of different anticoagulation regimens used pre-, intra-, and post-procedure.
- Evaluation of uninterrupted anticoagulation and heparin management.
Main Results:
- The incidence of thromboembolic and bleeding events varies (0.9%-5%) based on CAAF strategy and anticoagulation.
- Uninterrupted anticoagulation strategies are a key advance.
- Simplified LAA thrombus screening selection is an emerging effort.
Conclusions:
- Optimizing periprocedural anticoagulation is crucial for safe and effective CAAF.
- Individualized risk assessment and understanding anticoagulant pharmacokinetics are essential.
- Advances include uninterrupted anticoagulation and streamlined thrombus screening.
Introduction:
Atrial fibrillation (AF) is a cause of significant morbidity and mortality. Catheter ablation for AF (CAAF) has emerged as an effective treatment option of rhythm control for patients with symptomatic AF. However, the risk of thromboembolism and bleeding in the periprocedural period represent a worrisome complication of this therapy. The reported incidence of thromboembolic and bleeding events associated with CAAF varies from 0.9% to 5% depending on the CAAF strategy and the anticoagulation regimen used in the periprocedural period. Areas covered: The different anticoagulation regimens used prior to, during, and after CAAF to minimize the risk of thromboembolic and bleeding events are reviewed. The use of uninterrupted oral anticoagulation and appropriate heparin dosing to achieve safe activated clotting time levels are also detailed. A comprehensive approach with assessment of individual risk for thromboembolic and bleeding complications, and understanding the pharmacokinetics of the anticoagulant agents available is also reviewed. Expert opinion: The key advances done in the periprocedural anticoagulation field include the use of uninterrupted anticoagulation strategies in patients undergoing AF ablation and efforts to simplify the selection of patients who need LAA thrombus screening prior to ablation.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care